Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
4(44%)
Results Posted
0%(0 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
7
78%
Ph early_phase_1
1
11%

Phase Distribution

1

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 2Efficacy & side effects
7(87.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

4

trials recruiting

Total Trials

9

all time

Status Distribution
Active(4)
Completed(2)
Terminated(1)
Other(2)

Detailed Status

Active, not recruiting3
Completed2
unknown2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
4
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (12.5%)
Phase 27 (87.5%)

Trials by Status

completed222%
recruiting111%
terminated111%
unknown222%
active_not_recruiting333%

Recent Activity

4 active trials
Showing 5 of 9
active_not_recruitingphase_2

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

NCT05788081
active_not_recruitingphase_2

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

NCT03350126
active_not_recruitingphase_2

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

NCT04006262
terminatedphase_2

Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION

NCT04901988
unknownphase_2

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

NCT03879122
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05788081Phase 2

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Active Not Recruiting
NCT03350126Phase 2

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Active Not Recruiting
NCT04006262Phase 2

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Active Not Recruiting
NCT04901988Phase 2

Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION

Terminated
NCT03879122Phase 2

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Unknown
NCT03647839Phase 2

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Completed
NCT04866654Phase 2

Radiation Free Chemotherapy for Early Hodgkin Lymphoma

Recruiting
NCT04570683Early Phase 1

Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas

Unknown
NCT03132493

Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9